

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/609,233	06/27/2003	Imtiaz Chaudry	048765/277090	8210
826 7590 03/16/2007 ALSTON & BIRD LLP BANK OF AMERICA PLAZA 101 SOUTH TRYON STREET, SUITE 4000 CHARLOTTE, NC 28280-4000			EXAMINER	
			HAGHIGHATIAN, MINA	
			ART UNIT	PAPER NUMBER
			1616	
			MAII DATE	DEI WEDV VODE
		·	MAIL DATE	DELIVERY MODE
			03/16/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/609,233	CHAUDRY, IMTIAZ	
Examiner	Art Unit	
Mina Haghighatian	1616	

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 20 February 2007 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. 1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: The period for reply expires months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL 2. The Notice of Appeal was filed on _____. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). **AMENDMENTS** 3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: . (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). 5. Applicant's reply has overcome the following rejection(s): ___ 6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1,2,5,12-16,21,25-30,32,34,38-40 and 51-69. Claim(s) withdrawn from consideration: 6,7,10,11,17-20,22-24,33,35-37 and 41-50. AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e). 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER 11. 🛛 The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet. 12. ☐ Note the attached Information Disclosure Statement(s). (RTO/SB/08) Paper-No(sf) 2000 13. Other: ____. MANNAICHTEN SUPERVISORY PATENT EXAMINER GROUP 1250

Continuation of 11. does NOT place the application in condition for allowance because: The Amendments do not distinguish instant claims from prior art of reference and arguments are not persuasive. Applicant argues that William does not teach the recited concentration or the potential fill volume. Applicant argues that since the concentration range is not explicitly taught, "The Office MUST provide the rationale or evidence to support a showing of inherency". Arguments are not persuasive. It was clearly shown in the Final Office Action that Williams is teaching 1) formulations for inhalation comprising a hypertension reducing agent, 2) the unit doses and the total daily dose for the said formulations and treatments, 3) inhalation formulations comprising a liquid carrier, the medication and potential excipients. Williams does not explicitly disclose the concnetration range in mg/ml, however it would have been obvious to one of ordinary skill in the art that the concnetration of an active agent in a liquid base is disclosed in mg/ml. It is also known that the potency of a medicament administered by inhalation depends on the device used. For example, if the metered reservior of the metered dose inhaler holds 1 ml of a formulation, the required dose HAS to be in the 1 ml dispensed. The same argument also applies to the "fill volume". In other words, the prior art of reference provide sufficient informtaion to one of oedinary skill in the art to make and use the invention as claimed. Thus claims are not distinguished over the prior art of reference.